Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Relapsed/Refractory Waldenström Macroglobulinemia
CTR20190364Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Waldenström macroglobulinemia (WM), sponsored by InnoCare Pharma. Started Mar 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on CTR20190364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190364.